Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 6Stomach Neoplasms 5Melanoma 5Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 4Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Glioblastoma 4Breast Neoplasms 4Pancreatic Neoplasms 3Neoplasms 3Myelodysplastic Syndromes 3Glioma 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Sarcoma 2Rectal Neoplasms 2Peritoneal Neoplasms 2Osteosarcoma 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Mesothelioma, Malignant 2Lymphoma 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Diffuse Intrinsic Pontine Glioma 2Warts 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thrombocythemia, Essential 1

Interventions

Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Suspended × Biliary Tract Carcinoma × Clear all
NCT06199882 2024-10-15

SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma

Zhejiang Cancer Hospital

Phase 2 Suspended
34 enrolled
Gastrointestinal

Biliary Tract Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡